Screener
Niagen Bioscience NAGE Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Niagen Bioscience in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Niagen Bioscience’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:01 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001386570-26-000030
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Gain on sale of operating segment | 4,784 | — |
| Income before provision for income taxes | 6,735 | 5,231 |
| Provision for income taxes | 417 | 168 |
| Net income | $6,318 | $5,063 |
| Net income per share attributable to common stockholders: | ||
| Basic | $0.08 | $0.07 |
| Diluted | $0.07 | $0.06 |
| Weighted average common shares outstanding: |
Item 1. FINANCIAL STATEMENTS (unaudited)
FAQ
- What is Niagen Bioscience's net income?
- Niagen Bioscience (NAGE) reported net income of $6.32M in Q1 2026.
- How has Niagen Bioscience's net income changed year-over-year?
- Niagen Bioscience's net income increased by 24.8% year-over-year, from $5.06M to $6.32M.
- What is the long-term trend for Niagen Bioscience's net income?
- Over 3 years (2021 to 2025), Niagen Bioscience's net income has grown at a -13.8% compound annual growth rate (CAGR), from -$27.13M to $17.38M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Niagen Bioscience's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude